Announcement
19 Dec 2025
In December 2025, the United States government announced an agreement with Novartis to implement most-favoured-nation drug pricing for American patients.
Source
Sign in to access
Number of interventions
4
0 certainly harmful
4 likely harmful
0 liberalising
List of interventions
Implementation date
No implementation date
Revocation date:
No revocation date
Updated: 05 Apr 2026
Local operations incentive
Recent update from 05 Apr 2026:
On 19 December 2025, the U.S. Administration announced an agreement with Novartis. Under the agreement, Novartis expects to receive three years of relief from the potential Section 232 pharmaceutic...
Sign in to see more
Updated: 05 Apr 2026
FDI: Financial incentive
Recent update from 05 Apr 2026:
On 19 December 2025, the U.S. Administration announced an agreement with Novartis. Under the agreement, Novartis committed to make investments in R&D and manufacturing in the United States. In ...
Sign in to see more
Updated: 05 Apr 2026
Tax or social insurance relief
Recent update from 05 Apr 2026:
On 19 December 2025, the U.S. Administration announced reaching an agreement with Novartis. Under the agreement, Novartis expects to receive three years of tariff relief from the potential Section ...
Sign in to see more
Updated: 05 Apr 2026
Import tariff
Recent update from 05 Apr 2026:
On 19 December 2025, the United States announced an agreement with Novartis providing the company with three years of tariff relief from the potential Section 232 pharmaceutical tariffs. In exchang...
Sign in to see more
Threads
See all
This state act is not part of any Thread yet.